GlassScriptPhysician profile
Julie Medlin
NPI 1285729970
$3,682.84
in general payments reported to CMS, 2019-2025
19 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $452 · 2024: $1,539 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.52 |
| Education | $370.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $610.78 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $509.33 | 2022-2025 | Sotyktu |
| Abbvie INC. | $407.72 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $399.04 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $354.01 | 2023-2025 | Winlevi |
| Dermavant Sciences, INC. | $349.02 | 2023-2024 | Vtama |
| Incyte Corporation | $199.55 | 2024-2025 | Opzelura |
| Amgen INC. | $154.20 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $142.74 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Pfizer INC. | $114.28 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $91.41 | 2024-2025 | Zoryve |
| Genzyme Corporation | $81.23 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $75.35 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $52.35 | 2024-2025 | Libtayo, Dupixent |
| Organon LLC | $34.84 | 2025 | Vtama |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $33.46 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $30.77 | 2025 | Klisyri |
| Leo Pharma INC. | $22.03 | 2023 | Adbry |
| Botanix Sb INC | $20.73 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Medlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.